1-3 of 3
Oliver Schoor
Close
Sort by
Journal Articles

IMA402, an Off-the-Shelf, Next-Generation TCR Bispecific (TCER®) for Efficiently Targeting an HLA-Presented Peptide from the Pan-Cancer Antigen PRAME

Sebastian Bunk, Martin Hofmann, Gabriele Pszolla, Meike Hutt, Frank Schwöbel, Felix Unverdorben, Nadine Aschmoneit, Claudia Wagner, Maike Jaworski, Heiko Schuster, Florian Schwoerer, Christoph Schraeder, Oliver Schoor, Sarah Missel, Toni Weinschenk, Dominik Maurer, Carsten Reinhardt
Journal: Blood
Blood (2022) 140 (Supplement 1): 9089–9090.
https://doi.org/10.1182/blood-2022-165937
Published: 2022
Journal Articles

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER ® ) Molecules

Sebastian Bunk, PhD, Martin Hofmann, PhD, Felix Unverdorben, PhD, Meike Hutt, PhD, Gabriele Pszolla, PhD, Frank Schwöbel, PhD, Claudia Wagner, PhD, Sara Yousef, PhD, Heiko Schuster, PhD, Sarah Missel, PhD, Oliver Schoor, PhD, Toni Weinschenk, PhD, Harpreet Singh-Jasuja, PhD, Dominik Maurer, PhD, Carsten Reinhardt, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3368.
https://doi.org/10.1182/blood-2019-129958
Published: 2019
Journal Articles

The Effects of Imatinib on the Function of Monocyte Derived Dendritic Cells Are Mediated Via the Inhibition of Akt and NF-kappaB Signal Transduction Pathways.

Anette Rupf, MB, Silke Appel, PhD, Markus M. Weck, MS, Frank Grünebach, PhD, Lothar Kanz, MD, Oliver Schoor, MS, Tim H. Brümmendorf, MD, Toni Weinschenk, PhD, Peter Brossart, MD
Journal: Blood
Blood (2004) 104 (11): 3453.
https://doi.org/10.1182/blood.V104.11.3453.3453
Published: 2004